On January 3, 2022 Panolos Bioscience reported on the 27th that it has signed a joint research and development contract with AimedBio, a brain disease treatment development company, for brain tumor new drug ”PB101” (Press release, Panolos Bioscience, JAN 3, 2022, View Source [SID1234633688]). Panolos is a new drug development biotech based on a multifunctional recombinant protein platform.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
PB101 is currently in the preclinical toxicity test phase, and is aiming to apply for a phase 1 clinical trial protocol (IND) next year. In addition, Panolos has signed a consignment development (CDO) contract with Samsung Biologics for PB101.
Aimed Bio plans to cooperate with Panolos by participating in the establishment of strategies for preclinical and clinical development of PB101.
Specifically, in this joint study, AimedBio selected indications for clinical development of PB101 through big data-based biomarker selection and PDC/PDX (patient derived cell/patient derived xenograft) experiments, as well as clinical trials such as non-clinical research and development of combined administration. We plan to collaborate to increase the test success rate.
PB101 is VEGF-Grab, a fusion protein in which IgG1 Fc is coupled with glycosylated VEGF1 receptor (VEGFR1). According to Panolos, PB101 can suppress all angiogenic factors such as VEGF-A, VEGF-B, and placental growth factor (PlGF) that are overexpressed in the tumor microenvironment.
Avastin, a VEGF drug currently on the market, inhibits VEGF-A, while Eylia mainly inhibits VEGF-A/B with VEGF-Trap. In addition, PIGF expression increases with the administration of existing VEGF drugs, and PIGF overexpression is associated with poor prognosis of patients, so higher anticancer efficacy is expected as PIGF is inhibited.
In addition, as a result of recent preclinical studies, it was confirmed that Panolos is superior to existing VEGF drugs in terms of cancer cell growth inhibition, blood vessel normalization, and tumor microenvironment control. The company expects additional efficacy when administered in combination with immune checkpoint inhibitors.
Nam Do-hyun, CEO of AimdBio, said, "Intractable solid cancers, including brain tumors, do not have treatments and have high unmet needs. Selecting the correct indication and establishing a clinical development strategy accordingly determines the success of new drug development." Through collaboration with transplant models and clinical experts, we want to make PB101 a success story for the solid cancer market where there is no current treatment."
Meanwhile, Panolos is building a follow-up bi-antibody/multi-antibody project that attaches additional tumor targeting and immune activating factors based on PB101 ”αARTTM”, which inhibits multiple angiogenesis factor targets.